Latest Company News
- Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.
- Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio
- Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs
- Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion
READ ALL COMPANY NEWS IN THE COMPLETE COMPANY CREDIT REPORT